tirzepatide cardiovascular outcomes with Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular In the SUMMIT trial, researchers
Description
Dulaglutide alone and in combination with empagliflozin attenuate inflammatory pathways and microbiome dysbiosis in a non-diabetic mouse model of NASH
Epub 2023 Mar 16
Our model is tailored to provide you with personalized, effective care from start to finish
doi: 10.1002/cbic.201000717
A wide-ranging survey by market research company MMR Research interviewed 974 people in the UK, of whom 518 were currently using the drugs
